Articles

An ASCO expert panel has developed a comprehensive guideline for immunotherapy and targeted therapy in patients with advanced gastroesophageal cancer.1 The guideline is based on the many recent advances in immunotherapy and targeted therapy. “The role of immunotherapy has changed practice in the past 18 months, so this topic is very timely,” said lead author and…

The FDA has cleared an investigational new drug (IND) application to evaluate BA3182 for the treatment of patients with advanced adenocarcinoma, according to BioAtla, Inc. As a result of the IND, the company plans to initiate and advance a phase 1 dose-escalation and dose-expansion clinical trial in 2023, which will evaluate the safety, pharmacokinetics, and…

Positive results reported by Astellas Pharma regarding its novel Claudin 18.2-targeting antibody, zolbetuximab, suggest that an approval in front-line gastric and gastroesophageal junction (GEJ) adenocarcinoma is not far off. Two Phase III studies, SPOTLIGHT (NCT03504397) and GLOW (NCT03653507), examined the efficacy of monoclonal antibody zolbetuximab in patients deemed to have high expression of Claudin 18.2 (characterised as…

The KEYNOTE-859 trial is evaluating Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy in 1,579 patients with HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Gastric cancer is the fifth most diagnosed cancer and the fourth leading cause of cancer deaths worldwide, with nearly 1.1 million new cases diagnosed and more…

Diagnosing gastrointestinal disorders is an uncomfortable process. It might involve sticking a long tube with a camera attached down a patient’s throat, or inserting a small catheter through a patient’s nostril. Read more>

BOSTON, Ma. – Fifty-four-year-old Beth Lambert comes from a big family. She’s one of five siblings, but in 2006, her brother Steve died from a rare form of stomach cancer. “Just watching our brother go from someone who was so full of life, and he really was as much as he could be up until…

BALTIMORE —In this Woman’s Doctor segment, we take a closer look at stomach cancer. It’s a disease increasing among Americans under 50, particularly women. That’s according to a study by the National Cancer Institute which tracked the incidence of lower stomach cancer in the United States. Mercy Medical Center Dr. Vadim Gushchin said the incidence…

The rate of stomach cancer is increasing among Americans under 50, particularly women, according to a study by the National Cancer Institute. Researchers tracked the incidence of lower stomach cancer in the United States. Mercy Medical Center surgical oncologist Dr. Vadim Gushchin said the incidence of gastric cancer is very low in the U.S. and…

The American Society of Clinical Oncology (ASCO) has released new guidelines providing recommendations for the optimal treatment of patients with advanced gastroesophageal cancer following a systemic review of 18 randomized controlled trials by an expert panel. Read more>

Zolbetuximab in combination with a chemotherapy regimen including capecitabine and oxaliplatin (CAPOX) demonstrated positive results in patients with HER2-negative locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers, according to results of GLOW, a phase 3 clinical trial. Read more>